Publications by authors named "M L Idorn"
The continuous emergence of SARS-CoV-2 variants of concern has rendered many therapeutic monoclonal antibodies (mAbs) ineffective. To date, there are no clinically authorized therapeutic antibodies effective against the recently circulating Omicron sub-lineages BA.2.
View Article and Find Full Text PDFThe inhibition of heat shock protein 90 (HSP90), a molecular chaperone, has been proposed to be a potential novel treatment strategy for Coronavirus disease 2019 (COVID-19). In contrast to other studies, our data demonstrated that RGRN-305, a HSP90 inhibitor, exacerbated the cytopathic effect and did not reduce the viral shedding in VeroE6-hTMPRSS2 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Likewise in a murine model of SARS-CoV-2, transgenic mice treated orally with RGRN-305 exhibited reduced survival by the end of the experiment (day 12) as 14% (1/7) survived compared to 63% (5/8) of those treated with drug-vehicle.
View Article and Find Full Text PDFArticle Synopsis
- - The research identifies TMEFF1 as a critical factor that helps prevent the replication of the herpes simplex virus type 1 (HSV-1) in neurons, which are particularly vulnerable to damage from infection.
- - Using CRISPR screening, the study found that TMEFF1 is specifically expressed in central nervous system neurons and works by blocking viral entry, thereby reducing neuronal death during HSV-1 infection.
- - Experiments showed that mice lacking TMEFF1 were more susceptible to HSV-1 in the brain, highlighting its importance in combating viral infections in the central nervous system.
Article Synopsis
- * It analyzes various antibodies produced, including IgG, IgA, and IgM, specifically focusing on IgG subclasses (IgG1 and IgG4) and their effectiveness against different SARS-CoV-2 variants.
- * Results indicate that both vaccination and infections lead to a production of antibodies, which are crucial for inhibiting the virus, thus providing new insights into the immune response dynamics in the context of COVID-19.
Background: Capsid virus-like particles (cVLP) have proven safe and immunogenic and can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP COVID-19 vaccine in individuals who were naive to SARS-CoV-2.
Methods: In this phase 1, single-centre, dose-escalation, adjuvant-selection, open-label clinical trial, we recruited participants at the Radboud University Medical Center in Nijmegen, Netherlands, and sequentially assigned them to seven groups.